---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-189911"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:19:55.044750+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics appoints Dr. Neely Mozaffarian to Board, expanding to 10 members

## Summary
- Dr. Mozaffarian appointed effective July 29, 2024, as Class II director and member of NCG and Science & Technology committees.
- Board increased from 9 to 10 directors; Mozaffarian fills newly created vacancy.
- Received option to purchase 80,000 shares at July 29 closing price, vesting monthly over 36 months.
- Mozaffarian is CMO at Atomwise with over 20 years immunology/autoimmunity R&D leadership.
- Appointment adds expertise in autoimmune disease and cell therapy development.

## SEC filing metadata
- accession: 0001193125-24-189911
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312524189911/0001193125-24-189911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312524189911/d764342d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-189911
- JSON: https://secwatch.observer/filing/0001193125-24-189911.json
- Plain text: https://secwatch.observer/filing/0001193125-24-189911.txt

## Key facts
- Executive change
  Neelufar Mozaffarian was appointed as Class II director at FATE THERAPEUTICS INC.
  - Action: appointed
  - Role: Class II director
  source text: On July 29, 2024, the Board, following a recommendation from the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Neelufar Mozaffarian, M.D., Ph.D., FACR, to the Board, to serve as a Class II director and member of the NCG Committee and the Science and Technology Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312524189911/0001193125-24-189911-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.